Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


ABCG2- and ABCB1 inhibition using supratherapeutic doses of erlotinib: clinical implications in the treatment of CNS metastases.

van de Stadt EA, Yaqub M, Bahce I, Hendrikse NH.

J Nucl Med. 2019 Oct 4. pii: jnumed.119.235705. doi: 10.2967/jnumed.119.235705. [Epub ahead of print] No abstract available.


Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

Theelen WSME, Peulen HMU, Lalezari F, van der Noort V, de Vries JF, Aerts JGJV, Dumoulin DW, Bahce I, Niemeijer AN, de Langen AJ, Monkhorst K, Baas P.

JAMA Oncol. 2019 Jul 11. doi: 10.1001/jamaoncol.2019.1478. [Epub ahead of print]


Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer.

Niemeijer AN, Leung D, Huisman MC, Bahce I, Hoekstra OS, van Dongen GAMS, Boellaard R, Du S, Hayes W, Smith R, Windhorst AD, Hendrikse NH, Poot A, Vugts DJ, Thunnissen E, Morin P, Lipovsek D, Donnelly DJ, Bonacorsi SJ, Velasquez LM, de Gruijl TD, Smit EF, de Langen AJ.

Nat Commun. 2018 Nov 7;9(1):4664. doi: 10.1038/s41467-018-07131-y.


A protocol for urine collection and storage prior to DNA methylation analysis.

Bosschieter J, Bach S, Bijnsdorp IV, Segerink LI, Rurup WF, van Splunter AP, Bahce I, Novianti PW, Kazemier G, van Moorselaar RJA, Steenbergen RDM, Nieuwenhuijzen JA.

PLoS One. 2018 Aug 24;13(8):e0200906. doi: 10.1371/journal.pone.0200906. eCollection 2018.


A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor.

Petrulli JR, Hansen SB, Abourbeh G, Yaqub M, Bahce I, Holden D, Huang Y, Nabulsi NB, Contessa JN, Mishani E, Lammertsma AA, Morris ED.

Nucl Med Biol. 2017 Apr;47:56-61. doi: 10.1016/j.nucmedbio.2016.12.009. Epub 2017 Jan 2.


Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

Bahce I, Yaqub M, Smit EF, Lammertsma AA, van Dongen GA, Hendrikse NH.

Lung Cancer. 2017 May;107:1-13. doi: 10.1016/j.lungcan.2016.05.025. Epub 2016 May 31. Review.


Effects of erlotinib therapy on [(11)C]erlotinib uptake in EGFR mutated, advanced NSCLC.

Bahce I, Yaqub M, Errami H, Schuit RC, Schober P, Thunnissen E, Windhorst AD, Lammertsma AA, Smit EF, Hendrikse NH.

EJNMMI Res. 2016 Dec;6(1):10. doi: 10.1186/s13550-016-0169-8. Epub 2016 Feb 9.


Quantitative and Simplified Analysis of 11C-Erlotinib Studies.

Yaqub M, Bahce I, Voorhoeve C, Schuit RC, Windhorst AD, Hoekstra OS, Boellaard R, Hendrikse NH, Smit EF, Lammertsma AA.

J Nucl Med. 2016 Jun;57(6):861-6. doi: 10.2967/jnumed.115.165225. Epub 2016 Feb 4.


Multiparametric Analysis of the Relationship Between Tumor Hypoxia and Perfusion with ¹⁸F-Fluoroazomycin Arabinoside and ¹⁵O-H₂O PET.

Iqbal R, Kramer GM, Verwer EE, Huisman MC, de Langen AJ, Bahce I, van Velden FH, Windhorst AD, Lammertsma AA, Hoekstra OS, Boellaard R.

J Nucl Med. 2016 Apr;57(4):530-5. doi: 10.2967/jnumed.115.166579. Epub 2015 Dec 10.


A randomized phase II study comparing paclitaxel-carboplatin-bevacizumab with or without nitroglycerin patches in patients with stage IV nonsquamous nonsmall-cell lung cancer: NVALT12 (NCT01171170)†.

Dingemans AM, Groen HJ, Herder GJ, Stigt JA, Smit EF, Bahce I, Burgers JA, van den Borne BE, Biesma B, Vincent A, van der Noort V, Aerts JG; NVALT study group.

Ann Oncol. 2015 Nov;26(11):2286-93. doi: 10.1093/annonc/mdv370. Epub 2015 Sep 7.


Treatment and survival of patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastasis: A retrospective cohort analysis.

Kuiper JL, Hendriks LE, van der Wekken AJ, de Langen AJ, Bahce I, Thunnissen E, Heideman DA, Berk Y, Buijs EJ, Speel EJ, Krouwels FH, Smit HJ, Groen HJ, Dingemans AM, Smit EF.

Lung Cancer. 2015 Sep;89(3):255-61. doi: 10.1016/j.lungcan.2015.05.023. Epub 2015 Jun 6.


Pilot study of (89)Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer.

Bahce I, Huisman MC, Verwer EE, Ooijevaar R, Boutkourt F, Vugts DJ, van Dongen GA, Boellaard R, Smit EF.

EJNMMI Res. 2014 Dec;4(1):35. doi: 10.1186/s13550-014-0035-5. Epub 2014 Aug 2.


Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy.

Kuiper JL, Bahce I, Voorhoeve C, Yaqub M, Heideman DA, Thunnissen E, Paul MA, Postmus PE, Hendrikse NH, Smit EF.

Per Med. 2015 Mar;12(2):63-66. doi: 10.2217/pme.14.64.


Parametric methods for quantification of 18F-FAZA kinetics in non-small cell lung cancer patients.

Verwer EE, Bahce I, van Velden FH, Yaqub M, Schuit RC, Windhorst AD, Raijmakers P, Hoekstra OS, Lammertsma AA, Smit EF, Boellaard R.

J Nucl Med. 2014 Nov;55(11):1772-7. doi: 10.2967/jnumed.114.141846. Epub 2014 Oct 16.


Metabolic activity measured by FDG PET predicts pathological response in locally advanced superior sulcus NSCLC.

Bahce I, Vos CG, Dickhoff C, Hartemink KJ, Dahele M, Smit EF, Boellaard R, Hoekstra OS, Thunnissen E.

Lung Cancer. 2014 Aug;85(2):205-12. doi: 10.1016/j.lungcan.2014.04.010. Epub 2014 Apr 29.


Semiautomated volumetric response evaluation as an imaging biomarker in superior sulcus tumors.

Vos CG, Dahele M, van Sörnsen de Koste JR, Senan S, Bahce I, Paul MA, Thunnissen E, Smit EF, Hartemink KJ.

Strahlenther Onkol. 2014 Feb;190(2):204-9. doi: 10.1007/s00066-013-0482-3. Epub 2013 Dec 22.


Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients.

Verwer EE, van Velden FH, Bahce I, Yaqub M, Schuit RC, Windhorst AD, Raijmakers P, Lammertsma AA, Smit EF, Boellaard R.

Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1523-31. doi: 10.1007/s00259-013-2462-3. Epub 2013 Jun 6.


CT-perfusion versus [(15)O]H2O PET in lung tumors: effects of CT-perfusion methodology.

Kramer GM, Yaqub M, Bahce I, Smit EF, Lubberink M, Hoekstra OS, Boellaard R.

Med Phys. 2013 May;40(5):052502. doi: 10.1118/1.4798560.


Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.

Bahce I, Smit EF, Lubberink M, van der Veldt AA, Yaqub M, Windhorst AD, Schuit RC, Thunnissen E, Heideman DA, Postmus PE, Lammertsma AA, Hendrikse NH.

Clin Cancer Res. 2013 Jan 1;19(1):183-93. doi: 10.1158/1078-0432.CCR-12-0289. Epub 2012 Nov 7.


Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

Van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, Hendrikse NH, Eriksson J, Windhorst AD, Postmus PE, Verheul HM, Serné EH, Lammertsma AA, Smit EF.

Cancer Cell. 2012 Jan 17;21(1):82-91. doi: 10.1016/j.ccr.2011.11.023.

Supplemental Content

Support Center